{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T06:56:35Z","timestamp":1773212195716,"version":"3.50.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To prepare oral controlled-release cilostazol formulations and evaluate their pharmacokinetics and pharmacodynamics in dogs and humans compared with a commercial twice-daily immediate-release formulation (Pletal), thereby showing the potential for the development of an improved once-daily cilostazol formulation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Six different controlled-release preparations were formulated using a micronized cilostazol, solubilizer\/absorption enhancer and erodible hydrogel. In-vitro drug release profiles were tailored by varying hydrogel viscosity. Pharmacokinetics and pharmacodynamic (antithrombotic) efficacy were evaluated in beagle dog model of arterial thrombosis. Finally, their pharmacokinetics and pharmacodynamics were also evaluated in healthy human volunteers after single and multiple oral administrations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key findings<\/jats:title>\n                  <jats:p>Hydrogel viscosity-dependent sustained drug release profiles were observed with zero-order release kinetics during 8\u201312 h. In dogs and humans, compared with Pletal, prolonged drug absorption profiles were observed in the two controlled-release formulations studied. In dogs, the controlled-release formulations showed greater antithrombotic efficacy than twice-daily Pletal. In humans, the antithrombotic efficacy of the selected once-daily cilostazol formulation was equivalent to that of twice-daily Pletal after single and multiple administrations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The prepared oral controlled-release cilostazol formulation may provide prolonged drug absorption and sufficient therapeutic efficacy, potentially serving as an oral once-daily cilostazol formulation to improve patient compliance.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1111\/jphp.12227","type":"journal-article","created":{"date-parts":[[2014,2,24]],"date-time":"2014-02-24T17:19:12Z","timestamp":1393262352000},"page":"961-974","source":"Crossref","is-referenced-by-count":7,"title":["Preparation and evaluation of oral controlled-release cilostazol formulation: pharmacokinetics and antithrombotic efficacy in dogs and healthy male Korean participants"],"prefix":"10.1093","volume":"66","author":[{"given":"Kwang-Hyun","family":"Shin","sequence":"first","affiliation":[{"name":"College of Pharmacy, Chungnam National University , Daejeon,","place":["Republic of Korea"]},{"name":"R&D Team, Pacificpharma Co. , Yongin-si,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goo","family":"Yoon","sequence":"additional","affiliation":[{"name":"College of Pharmacy and Natural Medicine Research Institute, Mokpo National University , Muan-gun, Jeonnam,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In-Soo","family":"Yoon","sequence":"additional","affiliation":[{"name":"College of Pharmacy and Natural Medicine Research Institute, Mokpo National University , Muan-gun, Jeonnam,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Woo","family":"Park","sequence":"additional","affiliation":[{"name":"College of Pharmacy and Natural Medicine Research Institute, Mokpo National University , Muan-gun, Jeonnam,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,7,1]]},"reference":[{"key":"2024103109151442600_jphp12227-cit-0001","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.2174\/1381612033453910","article-title":"Cilostazol as a unique antithrombotic agent","volume":"9","author":"Kambayashi","year":"2003","journal-title":"Curr Pharm Des"},{"key":"2024103109151442600_jphp12227-cit-0002","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1046\/j.1463-1326.2002.0040s2s14.x","article-title":"The pharmacology of cilostazol","volume":"4","author":"Schror","year":"2002","journal-title":"Diabetes Obes Metab"},{"key":"2024103109151442600_jphp12227-cit-0003","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1160\/TH11-01-0041","article-title":"Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy","volume":"106","author":"Angiolillo","year":"2011","journal-title":"Thromb Haemost"},{"key":"2024103109151442600_jphp12227-cit-0004","first-page":"11","article-title":"Cilostazol: a novel treatment option in intermittent claudication","volume":"119","author":"Cariski","year":"2001","journal-title":"Int J Clin Pract Suppl"},{"key":"2024103109151442600_jphp12227-cit-0005","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1161\/01.CIR.98.7.678","article-title":"Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial","volume":"98","author":"Dawson","year":"1998","journal-title":"Circulation"},{"key":"2024103109151442600_jphp12227-cit-0006","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1160\/TH10-04-0239","article-title":"Enhanced platelet inhibition by adjunctive cilostazol to dual antiplatelet therapy after drug-eluting stent implantation for complex lesions","volume":"104","author":"Jeong","year":"2010","journal-title":"Thromb Haemost"},{"key":"2024103109151442600_jphp12227-cit-0007","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/S0002-9149(97)00173-2","article-title":"Use of cilostazol, a novel antiplatelet agent, in a post-Palmaz-Schatz stenting regimen","volume":"79","author":"Ochiai","year":"1997","journal-title":"Am J Cardiol"},{"key":"2024103109151442600_jphp12227-cit-0008","first-page":"1143","article-title":"Pharmacological properties of the novel anti-platelet aggregating agent 4-cyano-5,5-bis(4-methoxyphenyl)-4-pentenoic acid","volume":"37","author":"Fujimori","year":"1987","journal-title":"Arzneimittelforschung"},{"key":"2024103109151442600_jphp12227-cit-0009","first-page":"1189","article-title":"Antiaggregatory effect of oral cilostazol and recovery of platelet aggregability in patients with cerebrovascular disease","volume":"35","author":"Yasunaga","year":"1985","journal-title":"Arzneimittelforschung"},{"key":"2024103109151442600_jphp12227-cit-0010","first-page":"1144","article-title":"Effect of cilostazol on platelet aggregation and experimental thrombosis","volume":"35","author":"Kimura","year":"1985","journal-title":"Arzneimittelforschung"},{"key":"2024103109151442600_jphp12227-cit-0011","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jconrel.2005.11.013","article-title":"Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs","volume":"111","author":"Jinno","year":"2006","journal-title":"J Control Release"},{"key":"2024103109151442600_jphp12227-cit-0012","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1002\/jps.10490","article-title":"Limited influence of P-glycoprotein on small-intestinal absorption of cilostazol, a high absorptive permeability drug","volume":"92","author":"Toyobuku","year":"2003","journal-title":"J Pharm Sci"},{"key":"2024103109151442600_jphp12227-cit-0013","doi-asserted-by":"publisher","DOI":"10.3109\/03639045.2013.831439","article-title":"In vitro-in vivo extrapolation (IVIVE) for predicting human intestinal absorption and first-pass elimination of drugs: principles and applications","author":"Cho","year":"2013","journal-title":"Drug Dev Ind Pharm"},{"key":"2024103109151442600_jphp12227-cit-0014","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1067\/mcp.2002.122474","article-title":"Pharmacokinetic and pharmacodynamic modeling of the antiplatelet and cardiovascular effects of cilostazol in healthy humans","volume":"71","author":"Woo","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"2024103109151442600_jphp12227-cit-0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00003088-199937002-00002","article-title":"Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics","volume":"37","author":"Bramer","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"2024103109151442600_jphp12227-cit-0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-199937002-00001","article-title":"Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease","volume":"37","author":"Bramer","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"2024103109151442600_jphp12227-cit-0017","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0378-5173(01)00596-8","article-title":"Polymer particle erosion controlling drug release. I. Factors influencing drug release and characterization of the release mechanism","volume":"217","author":"Zuleger","year":"2001","journal-title":"Int J Pharm"},{"key":"2024103109151442600_jphp12227-cit-0018","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0169-409X(01)00112-0","article-title":"Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC)","volume":"48","author":"Siepmann","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"key":"2024103109151442600_jphp12227-cit-0019","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jconrel.2009.09.011","article-title":"Towards elucidation of the drug release mechanism from compressed hydrophilic matrices made of cellulose ethers. II. Evaluation of a possible swelling-controlled drug release mechanism using dimensionless analysis","volume":"141","author":"Ferrero","year":"2010","journal-title":"J Control Release"},{"key":"2024103109151442600_jphp12227-cit-0020","first-page":"1","article-title":"Absorption enhancers","volume":"7","author":"Muranishi","year":"1990","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"2024103109151442600_jphp12227-cit-0021","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0378-5173(95)00041-G","article-title":"Sodium lauryl sulphate increases tiludronate paracellular transport using human epithelial caco-2 monolayers","volume":"123","author":"Boulenc","year":"1995","journal-title":"Int J Pharm"},{"key":"2024103109151442600_jphp12227-cit-0022","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejphar.2006.11.003","article-title":"Cilostazol, a phosphodiesterase 3 inhibitor, protects mice against acute and late ischemic brain injuries","volume":"557","author":"Ye","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"2024103109151442600_jphp12227-cit-0023","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s005950170029","article-title":"Effect of cilostazol on endothelial cell denudation and proliferation in canine vein grafts","volume":"31","author":"Fuxiani","year":"2001","journal-title":"Surg Today"},{"key":"2024103109151442600_jphp12227-cit-0024","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1161\/01.ATV.13.4.563","article-title":"Cilostazol, a novel cyclic AMP phosphodiesterase inhibitor, prevents reocclusion after coronary arterial thrombolysis with recombinant tissue-type plasminogen activator","volume":"13","author":"Saitoh","year":"1993","journal-title":"Arterioscler Thromb"},{"key":"2024103109151442600_jphp12227-cit-0025","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1160\/TH06-08-0451","article-title":"Effect of antiplatelet agents clopidogrel, aspirin, and cilostazol on circulating tissue factor procoagulant activity in patients with peripheral arterial disease","volume":"96","author":"Rao","year":"2006","journal-title":"Thromb Haemost"},{"key":"2024103109151442600_jphp12227-cit-0026","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0002-9149(00)00695-0","article-title":"Increased platelet aggregability in response to shear stress in acute myocardial infarction and its inhibition by combined therapy with aspirin and cilostazol after coronary intervention","volume":"85","author":"Tanigawa","year":"2000","journal-title":"Am J Cardiol"},{"key":"2024103109151442600_jphp12227-cit-0027","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1055\/s-0037-1615217","article-title":"Effect of cilostazol on soluble adhesion molecules and platelet-derived microparticles in patients with diabetes","volume":"80","author":"Nomura","year":"1998","journal-title":"Thromb Haemost"},{"key":"2024103109151442600_jphp12227-cit-0028","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1053\/hj.1998.v136.93433","article-title":"Relation between inhibition of platelet aggregation and clinical outcomes","volume":"136","author":"Harrington","year":"1998","journal-title":"Am Heart J"},{"key":"2024103109151442600_jphp12227-cit-0029","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.thromres.2008.03.008","article-title":"Monitoring aspirin treatment in patients with thrombocytosis: comparison of the platelet function analyzer (PFA)-100 with optical aggregometry","volume":"123","author":"Tsantes","year":"2008","journal-title":"Thromb Res"},{"key":"2024103109151442600_jphp12227-cit-0030","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.blre.2004.05.002","article-title":"Platelet function analysis","volume":"19","author":"Harrison","year":"2005","journal-title":"Blood Rev"},{"key":"2024103109151442600_jphp12227-cit-0031","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0024-3205(97)00986-7","article-title":"nhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhibitor of cGMP-inhibited phosphodiesterase, in vitro and ex vivo","volume":"61","author":"Minami","year":"1997","journal-title":"Life Sci"},{"key":"2024103109151442600_jphp12227-cit-0032","first-page":"1163","article-title":"General pharmacological properties of cilostazol, a new antithrombotic drug. Part II: effect on the peripheral organs","volume":"35","author":"Shintani","year":"1985","journal-title":"Arzneimittelforschung"},{"key":"2024103109151442600_jphp12227-cit-0033","first-page":"1531","article-title":"Effects of cilostazol on platelet function","volume":"39","author":"Uehara","year":"1989","journal-title":"Arzneimittelforschung"},{"key":"2024103109151442600_jphp12227-cit-0034","first-page":"1186","article-title":"Clinical effects of oral cilostazol on suppression of platelet function in patients with cerebrovascular disease","volume":"35","author":"Yasunaga","year":"1985","journal-title":"Arzneimittelforschung"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjphp.12227","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjphp.12227","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/66\/7\/961\/60251615\/jphp12227.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/66\/7\/961\/60251615\/jphp12227.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T09:17:23Z","timestamp":1730366243000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/66\/7\/961\/6128129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,1]]},"references-count":34,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2014,7,1]]},"published-print":{"date-parts":[[2014,7,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jphp.12227","relation":{},"ISSN":["0022-3573","2042-7158"],"issn-type":[{"value":"0022-3573","type":"print"},{"value":"2042-7158","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,7]]},"published":{"date-parts":[[2014,7,1]]}}}